

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

Received: 2002.04.05
 Accepted: 2002.06.10
 Published: 2002.09.09

Superoxide dismutase – applications and relevance to human diseases

Rana Noor, Sonali Mittal, Jawaid Iqbal

Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India

Summary

Reactive oxygen species, such as superoxide radicals, are thought to underlie the pathogenesis of various diseases. Almost 3 to 10% of the oxygen utilized by tissues is converted to its reactive intermediates, which impair the functioning of cells and tissues. Superoxide dismutase (SOD) catalyzes the conversion of single electron reduced species of molecular oxygen to hydrogen peroxide and oxygen. There are several classes of SOD that differ in their metal binding ability, distribution in different cell compartments, and sensitivity to various reagents. Among these, Cu, Zn superoxide dismutase (SOD1) is widely distributed and comprises 90% of the total SOD. This ubiquitous enzyme, which requires Cu and Zn for its activity, has great physiological significance and therapeutic potential. The present review describes the role of SODs, especially Cu, Zn SOD, in several diseases, such as familial amyotrophic lateral sclerosis (FALS), Parkinson's disease, Alzheimer's disease, dengue fever, cancer, Down's syndrome, cataract, and several neurological disorders. Mutations in the SOD1 gene cause a familial form of amyotrophic lateral sclerosis. The mechanism by which mutant SOD1 causes the degeneration of motor neurons is not well understood. Transgenic mice expressing multiple copies of FALS-mutant SOD1s develop an ALS-like motor neuron disease. Vacuolar degeneration of mitochondria has been identified as the main pathological feature associated with motor neuron death and paralysis in several lines of FALS-SOD1 mice. Various observations and conclusions linking mutant SOD1 and FALS are discussed in this review in detail.

key words:

familial amyotrophic lateral sclerosis (FALS) • Parkinson's disease • Alzheimer's disease • oxidative damage • superoxide radical • Cu, Zn SOD

Full-text PDF: http://www.MedSciMonit.com/pub/vol_8/no_9/2653.pdf

Word count: 3428

Tables: –

Figures: –



References: 63

Author's address:

Jawaid Iqbal, Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh (U. P.) 202 002, India, email: j.iqbal@angelfire.com

BACKGROUND

Superoxide dismutase (SOD) is an enzyme catalyzing the disproportion of superoxide radicals to dioxygen and hydrogen peroxide, according to the following formulae:



SOD is found abundantly in many organisms, from microorganisms to plants and animals, since superoxide radicals are toxic to living cells, oxidizing and degrading biologically important molecules, such as lipids and proteins [1-4]. Several types of SOD, have been reported, based on the requirement of the metal species at the active site:

- (a) copper-and zinc-containing superoxide dismutase (Cu, Zn SOD)
- (b) Iron-containing superoxide dismutase (Fe SOD)
- (c) manganese-containing superoxide dismutase (Mn SOD) [5-7].

In addition, Ni-containing superoxide dismutase has recently been found in *Streptomyces griseus* and *S. coelicolor* [8-10].

Cu, Zn SODs have been isolated from a wide range of organisms, including yeast, spinach, chicken liver and bovine blood. In all these cases, a homodimeric enzyme is obtained, with a molecular weight of ~32,000 daltons and containing one Cu (II) and one Zn (II) per subunit. The subunits are stabilized by an intrachain disulfide bond, but associated by noncovalent forces. This enzyme requires Cu and Zn for its biological activity, and the loss of Cu results in its complete inactivation, leading in many cases to the development of human diseases [11]. Cu, Zn SOD has great physiological significance and therapeutic potential. The role of this enzyme has been investigated in various specific red blood cell (RBC) disorders, such as iron deficiency anemia, oxidative hemolytic anemia, thalassemia, sickle cell anemia, molecular dystrophy and cystic fibrosis, [12-15]. In recent studies, this enzyme has also been shown to be associated with dengue fever, postcholecystectomy pain syndrome, malign breast disease, steroid sensitive nephrotic syndrome and amyotrophic lateral sclerosis [16-18]. In rheumatoid arthritis, ischemic injury and cancer, SOD activity is considerably increased, suggesting a superoxide-related pathology and the involvement of SOD in these diseases. The principle aim of this article is to highlight the diseases associated with the expression of Cu, Zn SOD, as well as other superoxide dismutases.

DISEASES ASSOCIATED WITH Cu, ZN SUPEROXIDE DISMUTASE

Prion diseases are characterized by neurodegeneration, gliosis and accumulation of extracellular deposits of the

abnormal isoform of the prion protein (p, P^{sc}), sometimes in the form of plaques. Human prion diseases include Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker Syndrome, and Fatal Familial Insomnia [19,20]. It has been confirmed that prion protein expression regulates Cu incorporation into Cu, Zn SOD, thereby modulating its activity. This reduces cellular resistance to oxidative stress and may regulate other copper-dependent aspects of cell metabolism. There is a strong link between Alzheimer's disease and the activity of superoxide dismutase. A study of several elements of the antioxidative system – Cu, Zn superoxide dismutase (SOD), catalase (CAT), the glutathione system (GLU), chemiluminescence (CHE), and antioxidant capacity (AOX) – was conducted in patients with dementia of the Alzheimer type (DAT) and vascular dementia (VD) [21]. A significant association was found between the antioxidant variables measured in blood samples taken from these patients, demonstrating that VD and DAT diseases are accompanied by oxidative disorders. In a different study, the activity of Cu, Zn SOD was determined in red blood cell (RBC) homogenate obtained from demented patients with DAT, from their first degree relatives, and from healthy, non-related controls [22]. A statistically significant increase in SOD activity was found in RBC homogenate between the families of DAT patients and controls. This increase probably represents a general alteration of the oxidative processes characteristic of this dementia, which supports the proposal that this enzyme could be used as a peripheral early diagnostic marker of Alzheimer's disease (AD). In an animal model of Alzheimer-like vascular pathology and inflammatory reaction, the possibility has been explored of deleterious vascular actions and inflammatory response to the cytokine tumor necrosis factor, interleukin-1, and amyloid-beta, as well as the protective effects of superoxide dismutase [23]. Zemlan et al. [24] have monitored the activity of Cu, Zn SOD in fibroblast cell lines derived from familial Alzheimer's patients and normal controls. Cu, Zn SOD activity was found to be significantly elevated in the patients, supporting the earlier theory that paired helical filaments are synthesized in Alzheimer's disease by free radical hydroxylation of proline residues in paired helical filament precursor protein.

In addition to all these findings, one remarkable study has described the localization of Cu, Zn SOD in the brain tissues of patients with Alzheimer's disease [25]. Immunostaining experiments showed that large pyramidal neurons, which are potentially susceptible to degenerative processes in AD, contain higher amounts of Cu, Zn SOD than other brain cells.

Recently, extensive work has been carried out on the link between amyotrophic lateral sclerosis (ALS) and SOD. ALS is a devastating neurological disease that rapidly progresses from mild motor symptoms to severe motor paralysis and premature death. Kruman et al [26] have employed a mouse model of ALS in order to test the excitotoxicity hypothesis of ALS. In this model overexpression of a mutant familial ALS-linked Cu, Zn SOD leads to progressive motor neuron (MN) loss and a clinical phenotype remarkably similar to that of human

RA

ALS patients. Under basal culture conditions, MNs in mixed spinal cord culture from the Cu, Zn SOD mutant mice exhibited enhanced oxyradical production, lipid peroxidation, increased intracellular calcium levels, decreased intramitochondrial calcium levels, and mitochondrial dysfunction. In another study related to ALS, Vukosavic et al [27] have proposed that a mutation in the gene for Cu, Zn SOD, the only proven cause of ALS, induces the disease by a toxic property that promotes apoptosis. Further studies have been carried out in polypeptides of mutant Cu, Zn SOD in relation to ALS [28]. Ratovitski et al. [28] have shown that a mutation in the gene for Cu, Zn SOD causes a form of familial amyotrophic lateral sclerosis (FALS). In different kindreds, harboring different mutations, the duration of illness tends to be similar for a given mutation. For example, patients inheriting a substitution of valine for alanine at position 4 average a 1.5-year life expectancy after the onset of the symptoms, whereas patients harboring a substitution of arginine for histidine at position 46 (H46R) have an average 18-year life expectancy after disease onset. These studies show that 9 different FALS variants of SOD polypeptides appear to be soluble, but different mutant enzymes show a remarkable degree of variations with respect to activity, polypeptide half life, and resistance to proteolysis. Other studies related to ALS have confirmed that ALS is caused by a mutation in the gene for Cu, Zn SOD [29]. Transgenic mice expressing ALS-linked Cu, Zn SOD mutation exhibit a phenotype analogous to that of human ALS patients. In a recent study related to SOD and ALS [18], the aggregation of ubiquitin and a mutant ALS-linked Cu, Zn SOD protein correlates with disease progression and fragmentation of the Golgi apparatus (GA). In these studies, the transgenic mice that express the G93A mutation of human Cu, Zn SOD found in FALS showed the clinical symptoms and histopathological changes of sporadic ALS, including fragmentation of the neuronal GA. The finding of fragmented neuronal GA in asymptomatic mice, months before the onset of paralysis, suggests that the GA is an early target of the pathological processes causing neuronal degeneration. A subset of familial cases of ALS are linked to a missense mutation in the gene for Cu, Zn SOD [30]. Patients with such a missense mutation develop a paralytic disease indistinguishable from sporadic ALS, caused by the addition of an unknown function, which is toxic. Nitric oxide reacts with the superoxide anion to form the strong oxidant peroxynitrite, which is implicated in neuronal injury in a variety of model systems. Peroxynitrite is an alternate substrate for Cu, Zn SOD, causing catalytic nitration of its tyrosine residues in some patients. A mutation in the gene for Cu, Zn SOD may disrupt the active site of the enzyme and permit greater access of peroxynitrite to copper, leading to increased nitration by peroxynitrite of critical cellular targets. Kato et al [31] have characterized the neuronal Lewy body-like hyaline inclusions (LBHI) and astrocytic hyaline inclusions, which are the neuropathological markers of mutant SOD linked FALS.

The FALS mutations in the gene for Cu, Zn SOD are dominant, and are currently believed to exert their

effects because of a gain of function rather than a loss of activity. The most convincing evidence for such a gain of toxic function is the observation that the expression of FALS mutant human Cu, Zn SODs in transgenic mice causes motor neuron disease, while expression of wild type (wt) human Cu, Zn SOD does not [32-34]. Knockout mice that do not express Cu, Zn SOD also do not develop motor neuron disease [35]. The gain of function hypothesis is also supported by the observation that expression of FALS mutant human Cu, Zn SOD is pro-apoptotic in cultured neuronal cells, while wt human Cu, Zn SOD is antiapoptotic [36]. The expression of the FALS mutant but not wt human Cu, Zn SOD in a human neuroblastoma cell line induced a loss of mitochondrial membrane potential and an increase in cytosolic calcium concentration [37]. It is also very likely that oxidative damage occurs as a result of the peroxidative activity of FALS mutant Cu, Zn SOD, and can be hypothesized to arise from either or both of the following two mechanisms. 1) increased access of the substrate to the active site, leading to increased oxidation of the substrate 2) increased formation of OH radical due to the presence of Cu rather than Zn at the zinc site leading to a subpopulation of Cu, Cu-SOD that is more reactive. An intriguing third possibility is that increased production of OH radicals could lead to damaged inactive mutant SOD enzyme, which could slowly release free Cu ions catalyzing deleterious Fenton-type oxidation reactions at or near the sites where they are released. In this regard, further work is needed to test the ability of a variety of hydroxyl radical scavengers to slow the inactivation of wt and mutant enzymes in their Cu, Cu and Cu, Zn forms by reaction with hydrogen peroxide.

Based on the studies by Jaarsma et al [38] related to Cu, Zn SOD and FALS, the observation has been made that one of the most puzzling aspects of SOD1-linked FALS is the large number of different mutations that yield mutants having a marked variability of biochemical/biophysical properties, but all causing a rather similar disease phenotype [39-42]. Studies so far have failed to identify a critical toxic property that links the different mutants to the disease [41,42]. This may indicate that this common toxic property arises either from a hitherto unrecognized function or property of the SOD1 Protein, or from multiple factors that contribute to the deleterious action of mutant SOD1s. Since SOD1 is both potentially dangerous (because of its capacity to bind Cu and Zn) and abundant, it is highly likely that abnormalities related to its synthesis or degradation could disturb cell function.

The role of Cu, Zn SOD in several other diseases has also been thoroughly studied. Plasma and total antioxidant status in patients with benign and malignant breast disease has been studied by Afrasyap et al [43]. The study was carried out on 25 women with breast cancer, 25 with fibrocystic breast disease, and 19 healthy subjects. Antioxidant enzyme activities and total antioxidant status were measured in the erythrocytes and plasma of patients and healthy individuals. A positive correlation was found between erythrocytes and plasma Cu, Zn

SOD activity in all groups, indicating that enzymatic and non-enzymatic antioxidants are differentially altered in human breast tumors. Superoxide dismutase activity has been determined by Gonzales et al [17] in RBC isolated from patients with acute myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin's disease, lymphosarcoma and various visceral cancers. SOD activity was found to be significantly elevated in RBC from patients with acute myelogenous leukemia and lymphoproliferative syndromes. SOD activity levels further decrease with an increase in the duration of treatment. These results suggest an abnormality in the regulation of the expression of the SOD gene in the pluripotent stem cells. Built-in cellular defense mechanisms play a major role in tumor protection against non-surgical, antineoplastic therapies. Of these, the overexpression of antioxidant enzymes such as SOD may be the most important [44].

The role of free radicals and Cu, Zn SOD has also been investigated in neuronal injury [45]. Free radicals may play an important role in several pathological conditions of the central nervous system (CNS), where they directly injure tissue, and where their formation may also be a consequence of tissue injury. Free radicals produce tissue damage through multiple mechanisms and can worsen acute neurodegenerative disorders including Parkinson's disease. These diseases are linked to a missense mutation of Cu, Zn SOD. A correlation between OH radicals and Cu, Zn SOD activity in Parkinson's disease (PD) has also been suggested by the studies of Ihara et al [46]. The higher OH level and lower Cu, Zn SOD activity may play a role in the onset of progression of PD, and pergolite may act neuroprotectively by inducing Cu, Zn SOD. In general, therapeutic approaches which limit oxidative stress may be potentially beneficial in several neurological diseases. Grasbon Frodl et al [47] have identified two polymorphisms of the MnSOD gene associated with Parkinson's disease. The Nobel Prize for physiology and medicine in 2000 was awarded for findings showing that Parkinson patients have abnormally low concentrations of dopamine in the basal ganglia [48]. As a consequence L-Dopa was developed, as a drug against Parkinson's Disease, and it remains to this day the most important treatment method for this disease.

Recent findings on the etiology of cataract and age-related muscular degeneration (AMD) suggest the role of an oxidative mechanism in these diseases [49]. In these studies high levels of erythrocyte SOD activity was associated with a two-fold increase in nuclear cataract.

Pitkanan and Robinson [50] have studied complex I (NADH-CoQ reductase) in patients with fatal infantile lactic acidosis (FILA), cardiomyopathy with cataract (CC), hepatopathy with tubulopathy (HT), Leigh's disease (LD), cataracts and developmental delay (CD) and lactic acidemia in the neonatal period followed by mild symptoms (MS). The production of superoxide radicals, in addition to NADH, was measured. Superoxide production rates were highest with CD and decreased in the order CD >> MS > LD > Control > HT > FILA =

CC. The quantity of Mn superoxide dismutase (MnSOD) was highest in CC and FILA and lowest in CD. Given these observations, they hypothesized that oxygen radical production increases when complex I activity is compromised. Klaefer et al [51] have also confirmed that a higher level of Cu, Zn SOD can reduce the severity of oxygen-induced retinopathy in a mouse model.

The diseases associated with dengue fever include the classical dengue (DEN), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). SOD and other antioxidant proteins have been found to be abnormal in these diseases [16]. The preliminary report of dengue confirms the assumption of free radical generation and alteration in antioxidant status during acute illness. However, further studies are required to understand their complex interaction in disease progression and the possible therapeutic utility of the findings. Changes in Cu, Zn SOD activity have also been found in children with steroid-sensitive nephrotic syndrome (NS), implicating the role of free radicals in the development of this syndrome [52]. Erythrocyte antioxidant activity and trace element levels are also the best markers in Behcet's disease [53]. Selenium (Se), Zinc (Zn), Copper (Cu) and antioxidant enzymes, including SOD levels in sera, have been detected in Behcet patients. In this study, the SOD level was low in the serum of Behcet's disease patients. It has been suggested that decreased SOD activity and increased production of free oxygen radicals may play a role in the etiopathogenesis of this disease.

Antioxidant enzyme activity, especially Cu, Zn and Mn SOD, has also been studied in human abdominal aortic aneurysmal and occlusive diseases [54]. The activity of these enzymes was lowered in the tissue of these patients, which points to the involvement of free radicals. The plasma extracellular SOD levels in an Australian population with coronary artery disease were measured [55]. The results of these studies show an association between extracellular SOD (EC-SOD) and coronary artery disease. EC-SOD is considered to be more protective, contributing to reduced coronary risk. Down's syndrome (DS), which is characterized by premature aging, has also been related to oxidative stress, resulting from the aberrant expression of Cu, Zn SOD [56]. SOD activity has also been measured in the blood of different individuals between 50 to 93 years of age and the level of this important enzyme was found to decrease with age [57]. In diabetes, the persistence of hyperglycemia has been reported to cause increased production of oxygen free radicals through glucose autooxidation and nonenzymatic glycation. The highest erythrocyte SOD activity has been found in diabetic children at the onset of clinical diabetes. In diabetic adolescents, SOD activity is also significantly higher than in control subjects. Decreased antioxidant defenses may increase the susceptibility of diabetic patients to oxidative injury. Appropriate support for enhancing antioxidant supply in these young diabetic patients may help in preventing clinical complications during the course of the disease [58].

RA

There are other diseases that have close association with SOD, but our goal in this article is to focus on the most recent literature available related to those diseases discussed in the previous section. Studies on SOD in biological systems and the deleterious effect of the O_2 generating system on biological macromolecules, subcellular components, cells and tissues suggest that O_2 can be an initiating or contributing factor in most of these diseases. Superoxide-related pathology may result either from increased production of O_2 due to hyperoxia, activation of granulocytes and macrophages, conversion of xanthine dehydrogenase to xanthine oxidase, exposure to ionizing radiation and redox cycling of xenobiotics, or from decreased activity of SOD.

THERAPEUTIC POTENTIAL

Keeping in mind the association of SOD with so many diseases, it is equally important to highlight its therapeutic potential. SOD can be used in mustard gas (MS) burns [59]. MS has been used in chemical warfare since World War I. The blistering skin lesions are slow to heal. Secondary inflammation, as well as damage to organs distant from the original wound, can occur due to these burns. Presently there is no antidote for burns and poisoning by MS. A study by Eldad et al [59] has shown that treatment modalities with free oxygen radical scavengers, Cu, Zn and Mn SOD are effective for MS skin burns in an experimental guinea pig model. Each of the SOD compounds dramatically reduced the burn lesion area when administered intraperitoneally / intralesionally (i. p/i. l) before wound infliction. Studies conducted by Danel et al [60] have confirmed that gene therapy for oxidant injury-related diseases can be used to overcome oxidant injury by augmenting intercellular antioxidant enzymes. When adult rats were injected intratracheally with an adenovirus (Ad) vector encoding human Cu, Zn SOD or catalase cDNA, a mixture of both Ad vectors or a control Ad vector containing no exogenous gene, the expression of human catalase and Cu, Zn SOD was demonstrated 3 days later in distal lung epithelial cells and alveolar macrophages. After exposure to 100% O_2 for 62 hrs, survival was greater in rats injected with catalase and/or SOD Ad vectors than in control rats. A clinical trial has been performed for successful treatment of radiation-induced fibrosis using liposomal Cu, Zn SOD [61].

Koksoy et al [62] tried to compare the prophylactic effects of SOD, SOD + catalase, desferrioxamine, verapamil and disulfiram, all free oxygen radical scavengers, in an animal model of experimental acetic acid colitis. The positive effect of SOD on the recovery of human hemopoietic stem cells has been successfully shown by Ma et al. [63]. Their study demonstrated that the addition of SOD to hypothermic storage media may increase the recovery of hemopoietic stem cells.

CONCLUSION

From the literature available to date it is evident that free radical processes and the biological defenses against them are an important area of the biological response to

various diseases. The functional status of SOD1 could be considered a reliable index of the ability of the organism to withstand various pathological conditions. The full significance of SOD in the diagnosis and prophylaxis of various disease conditions is among the most crucial areas in modern biomedical and environmental research.

Acknowledgement

The authors would like to thank Dr. Riaz Mahmood (R.M.) for his valuable suggestions, and the Council of Scientific and Industrial Research (C.S.I.R.), New Delhi, India for their generous financial support.

REFERENCES:

1. Fridovich I: Superoxide radical and superoxide dismutase. *Ann Rev Biochem*, 1995; 64: 97-112
2. McCord JM: Superoxide radical, controversies, contradictions and paradoxes. *Proc Soc Exp Biol Med*, 1995; 209: 112-117
3. Iqbal J, Clerch LB, Hass MA et al: Endotoxin increases lung Cu, Zn superoxide dismutase mRNA: O_2 raises enzyme synthesis. *Am J Physiol: Lung Cell Mol Biol*, 1989; 257: 61-64
4. Hass MA, Iqbal J, Clerch LB et al: Rat lung Cu, Zn superoxide dismutase: isolation and sequence of full length cDNA and studies of enzyme induction. *J Clin Invest*, 1989; 83: 1241-1246
5. Fridovich I: Superoxide dismutase. *Adv Enzymol Relat, Areas Mol Biol*, 1986; 41: 35-47
6. Steinman H: Superoxide dismutase. Protein chemistry and structure-function relationship. In: Oberley LW (ed): *Superoxide dismutase*. vol. 1: 11-69. CRC press Boca Raton FL
7. Bennister JV, Bannister WH, Rotilio G: Aspects of the structure, function and applications of superoxide dismutase. *CRC Crit Rev Biochem*, 1987; 22: 111-180
8. Youn HD, Kim EJ, Roe JH et al: A novel nickel-containing superoxide dismutase from *Streptomyces* spp. *Biochem J*, 1996; 318: 889-896
9. Kim EJ, Kim HP, Hah YC, Roe JH: Differential expression of superoxide dismutase containing Ni and Fe/Zn in *Streptomyces coelicolor*. *Eur J Biochem*, 1996; 241: 178-189
10. Youn HD, Youn H, Lee JW et al: Unique enzyme of superoxide dismutase in *Streptomyces griseus*. *Arch Biochem Biophys*, 1996; 334: 341-348
11. Brown DR, Besinger A: Prion protein expression and superoxide dismutase activity. *Biochem J*, 1998; 334: 423-429
12. Pan chenko LF, Lamchingin T, Curasimov AM et al: Activity of superoxide dismutase in the blood of children with iron deficiency anemia. *Vopr Med Khim*, 1979; 25: 181-185
13. Mavelli I, Ciriolo MR, Rossi L et al: Favism: a hemolytic disease associated with increased superoxide dismutase and decreased glutathione peroxidase activities in red blood cells. *Eur J Biochem*, 1984; 139: 13-18
14. Concetti A, Massei P, Rotilio G et al: Superoxide dismutase in red blood cells: method of assay and enzyme content in normal subjects and in patients with B- thalassemia J. *Lab Clin Med*, 1976; 87: 1057-1064
15. Mizuno Y: Superoxide dismutase activity in early stages of development in normal and dystrophic chickens. *Life Sci*, 1984; 34: 909-914
16. Ray G, Kumar V, Kapoor AV et al: Status of antioxidants and other biochemical abnormalities in children with dengue fever. *J Trop Pediatr*, 1999; 45: 4-7
17. Gonzales R, Auclair C, Voisin E et al: Superoxide dismutase, catalase and glutathione peroxidase in red blood cells from patients with malignant disease. *Cancer Res*, 1984; 44: 4137-4139
18. Stieber AA, Gonatas JO, Gonatas NK: Aggregation of Ubiquitin and a mutant ALS-linked SOD 1 protein correlate with disease progression and fragmentation of Golgi apparatus. *J Neurol Sci*, 2000; 173: 53-62

19. Prusiner SB: Molecular biology of prion diseases. *Science*, 1991; 252: 1515-1522
20. Hsiao K, Prusiner SB: Inherited human prion diseases. *Neurology*, 1990; 40: 1820-1827
21. Famulari AL, Marschoff ER, Llesuy SF et al: The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and possible assay to differentiate demented subjects and controls. *J Neurol Sci*, 1996; 141: 69-78
22. Serra JA, Famulari AL, Kohan S et al: Copper Zinc superoxide dismutase activity in red blood cells in probable Alzheimer's patients and their first degree relatives. *J Neurol Sci*, 1994; 122: 179-188
23. Rhodin J, Thomas T, Bryant M, Sutton ET: Animal model of Alzheimer-like vascular pathology and inflammatory reaction. *Ann N Y Acad Sci*, 2000; 903: 345-352
24. Zemlan FP, Thienhaus OJ, Bosmann HB: Superoxide dismutase activity in Alzheimer's disease: Possible mechanism for paired helical filament formation. *Brain Res*, 1989; 476: 160-162
25. Delacourte A, Defossez A, Caballos I et al: Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. *Neurosci Lett*, 1988; 92: 247-253
26. Kruman II, Pedersen WA, Springer JE, Mattson MP: ALS-linked Cu/Zn mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. *Exp Neurol*, 1999; 160: 28-39
27. Vukosavic S, Dubois DM, Romero N, Przedborski S: Bax and BCL-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. *J Neurochem*, 1999; 73: 2460-2468
28. Ratovitski T, Corson LB, Strain J et al: Variation in the biochemical/biophysical properties of mutant superoxide dismutase enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. *Hum Mol Genet*, 1999; 8: 1451-1460
29. Pedersen WA, Mattson MP: No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Zn superoxide dismutase mutant mice. *Brain Res*, 1999; 833: 117-120
30. Facchinetti F, Sasaki M, Cutting FB et al: Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. *Neuroscience*, 1999; 90: 1483-1492
31. Kato S, Saito M, Hirano A, Ohama E: Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation: neuronal Lewy body-like hyaline inclusions and astrocytic hyaline inclusions. *Histol Histopathol*, 1999; 14: 973-980
32. Gurney ME, Pu H, Chiu AY et al: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. *Science*, 1994; 264: 1772-1775
33. Gurney ME: Transgenic animal models of familial amyotrophic lateral sclerosis. *J Neurol*, 1997; 244: 515-520
34. Dalcanto MC, Gurney ME: A low expressor line of transgenic mice carrying a mutant human Cu, Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. *Acta Neuropathol*, 1997; 93: 537-550
35. Reaume AG, Elliot JL, Hoffman EK et al: Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. *Natl Genet*, 1996; 13: 43-47
36. Rabizadeh S, Gralla EB, Borchelt DR et al: Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. *Proc Natl Acad Sci USA*, 1995; 92: 3024-3028
37. Carri MT, Ferri A, Batissoni A et al: Expression of Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca²⁺ concentration in transfected neuroblastoma SH-SY5Y cells. *FEBS Lett*, 1997; 414: 365-368
38. Jaarsma D, Haasdijk ED, Grashorn JAC et al: Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration and premature motoneuron death and accelerates motoneuron disease in mice expressing a Familial Amyotrophic Lateral Sclerosis mutant SOD1. *Neurobiol Diseases*, 2000; 7: 623-643
39. Marklund SL, Andersen PM, Forsgren L et al: Normal binding and reactivity of copper in mutant superoxide dismutase isolated from amyotrophic lateral sclerosis patients. *Neurochem*, 1997; 69: 675-681
40. Ogawa Y, Kosaka H, Nakanishi T et al: Stability of mutant superoxide dismutase-1 associated with familial amyotrophic lateral sclerosis determines the manner of copper release and induction of thioredoxin in erythrocytes. *Biochem Biophys Res Commun*, 1997; 241: 251-257
41. Ratovitski A, Leigh PN: Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: Correlation between genotypes and clinical features. *Neural Neurosurg Psychol*, 1996; 61: 565-572
42. Siddiqui T ALS: Molecular clues to the jigsaw puzzle of neuronal degeneration. *Cold Spring Harbor Symp. Quant Biol*, 1996; 61: 699-708
43. Afrasyap L, Guvenen G, Turkmen S: Plasma and erythrocyte total antioxidant status in patients with benign and malignant breast disease. *Cancer Biochem, Biophys*, 1998; 16: 129-138
44. Kong Q, Lillehei KO: Antioxidant inhibitors for cancer therapy. *Med Hypothesis*, 1998; 51: 405-409
45. Facchinetti F, Dawson VL, Dawson TM: Free radicals as mediators of neuronal injury. *Cell Mol Neurobiol*, 1998; 18: 667-682
46. Ihara Y, Chuda M, Kuroda S, Hayabara T: Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: Relationship to clinical data. *J Neurol Sci*, 1999; 170: 90-95
47. Grasbon Frodl EM, Kosel S, Riess O et al: Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. *Biochem Biophys Res Commun*, 1999; 255: 749-752
48. Carlsson A, Greengard P, Kandel E: Signal transduction in the nervous system. *Nobel Prize in Physiology and Medicine*, 2000
49. Delcourt C, Cristol JP, Leyer CL et al: Association of antioxidant enzymes with cataract and age-related muscular degeneration. *Ophthalmology*, 1999; 106: 215-222
50. Pitkanan S, Robinson BH: Mitochondrial Complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. *J Clin Invest*, 1996; 98: 345-351
51. Klaeger C, desa L, Klaeger AJ et al: An elevated level of copper zinc superoxide dismutase fails to prevent oxygen-induced retinopathy in mice. *Br J Ophthalmol*, 1996; 80: 429-434
52. Fydyk J, Jacobson E, Kurawska O et al: Antioxidant status of children with steroid-sensitive nephrotic syndrome. *Pediatr Nephrol*, 1998; 12: 751-754
53. Tuzun A, Aydin A, Turan M: Erythrocyte antioxidant activity and trace element levels in Behcet's disease. *Biol Trace Elem Res*, 1998; 64: 169-174
54. Dubick MA, Kun CL, Disilvestro RA et al: Antioxidant enzyme activity in human abdominal aortic aneurysms and occlusive disease. *Proc Soc Exp Biol Med*, 1999; 220: 39-45
55. Wang XL, Adachi T, Sim AS, Wilken DC: Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. *Arterioscler Tromb Vasc Biol*, 1998; 18: 1915-1921
56. Druzhyna N, Nair RG, LeDoux SP, Wilson CL: Defective repair of oxidative damage in mitochondrial DNA in Down's Syndrome. *Mutat Res*, 1998; 409: 81-89
57. Casado A, dela Torri R, Lopez-Fernandez E et al: Superoxide, dismutase and catalase levels in diseases of the aged. *Gac Med Mex*, 1998; 134: 539-544
58. Dominguez C, Ruiz E, Gussiny M, Carrascosa A: Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. *Diabetes care*, 1998; 21: 1736-1742
59. Eldad A, Ben Meir, D Breiterman S et al: Superoxide dismutase (SOD) for mustard gas burns. *Burns*, 1998; 24: 114-119
60. Danel C, Erzurum SC, Prayssac P et al: Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNA protects against hyperoxia but not against ischemia reperfusion lung injury. *Human Gene Ther*, 1998; 9: 1487-1496
61. Delanian S, Baillet F, Huart J et al: Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trials. *Radiother, Oncol*, 1997; 42: 12-20
62. Koksoy FN, Kose H, Soybir GR et al: The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. *J R Coll Surg Edinb*, 1997; 42: 27-30
63. Ma EP, Liu XZ, Liu MD et al: The effect of superoxide dismutase on the recovery of human bone marrow hemopoietic stem cells stored at 4°C. *Cryobiology*, 1998; 37: 372-375

RA